REGN 3918

Drug Profile

REGN 3918

Alternative Names: REGN3918

Latest Information Update: 07 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 07 May 2017 Pharmacokinetics data from a preclinical study released by Regeneron
  • 01 Apr 2017 Phase-I clinical trials in Paroxysmal nocturnal haemoglobinuria (In volunteers) in United Kingdom (IV) (NCT03115996)
  • 01 Apr 2017 Phase-I clinical trials in Paroxysmal nocturnal haemoglobinuria (In volunteers) in United Kingdom (SC) (NCT03115996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top